Source-grounded facts extracted from CareDx, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CareDx, Inc. shareholders approved To approve the amendment of the Company’s 2024 Equity Incentive Plan to increase the available shares reserved thereunder. at the 2026-06-11 meeting.
“Proposal 5: Approval of the amendment of the Company’s 2024 Equity Incentive Plan. Shares For Shares Against Shares Abstaining Broker Non-Votes 27,575,633 13,702,645 34,744 6,829,710 The Company’s stockholders voted to approve the Plan Amendment.”
CareDx, Inc. shareholders voted on To approve, on a non-binding advisory basis, of the frequency of advisory votes on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2026-06-11 meeting.
“Proposal 4: Approval, on a non-binding advisory basis, of the frequency of advisory votes on the compensation of the Company’s named executive officers. One Year Two Years Three Years Abstaining Broker Non-Votes 39,804,235 64,263 1,416,678 27,846 6,829,710 The Company’s stockholders advised that they were in favor of “one year” as the frequency of holding future advisory votes on the compensation of the Company’s named executive officers. Based on the results of the advisory vote, the Company’s Board of Directors has determined that the Company will hold an advisory vote on the compensation of its named executive officers every one year.”
CareDx, Inc. shareholders approved To approve, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2026-06-11 meeting.
“Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Shares For Shares Against Shares Abstaining Broker Non-Votes 39,387,247 1,905,070 20,705 6,829,710 The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.”
CareDx, Inc. shareholders approved To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-11 meeting.
“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Shares For Shares Against Shares Abstaining Broker Non-Votes 48,012,497 111,586 18,649 — The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026.”
CareDx, Inc. shareholders approved To elect Fred E. Cohen, M.D., D. Phil, R. Bryan Riggsbee and Suresh Gunasekaran as Class II directors, and Michael D. Goldberg and John W. Hanna as Class III directors, each to serve a one-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective at the 2026-06-11 meeting.
“Proposal 1: Election of three Class II directors and two Class III directors, identified in the table below, each to serve a one-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier death, resignation or removal. Nominees Class Shares For Shares Withheld Broker Non-Votes Fred E. Cohen, M.D., D. Phil II 40,271,984 1,041,038 6,829,710 R. Bryan Riggsbee II 38,851,207 2,461,815 6,829,710 Suresh Gunasekaran II 41,091,649 221,373 6,829,710 Michael D. Goldberg III 38,837,463 2,475,559 6,829,710 John W. Hanna III 40,812,915 500,107 6,829,710 Each of the five nominees for director was elected to serve until the Company’s 2027 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal.”
CareDx, Inc. reported the first quarter ended March 31, 2026 results: revenue $118 million, net income $3 million, EPS $0.05. Guidance raised.
“for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights · Revenue of $118 million, an increase of 39% year-over-year · Testing services revenue of $91 million, an increase of 48% year-over-year, and testing services volume of approximately 54,900, an increase”
CareDx, Inc. entered into Merger Agreement with Naveris, Inc., Nautilus Merger Sub, Inc., and Shareholder Representative Services LLC valued at $160.0 million in cash, subject to certain customary adjustments, and up to $100.0 million in additi (effective 2026-04-28).
“On April 28, 2026, CareDx, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Naveris, Inc., a Delaware corporation (“Naveris”), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC”
CareDx, Inc. reported first quarter of 2026 results: revenue approximately $118 million.
“Revenue of approximately $118 million, growth of 39% year-over-year”
CareDx, Inc. entered into Purchase Agreement with Eurobio Scientific S.A. valued at $170 million in cash (effective 2026-04-15).
“On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software (the “Business”) for $170 million in cash”
CareDx, Inc.: Changed voting standard for director elections from plurality to majority vote in uncontested elections and adopted a director resignation policy for incumbents who do not receive a majority vote (effective 2025-12-12).
“On December 12, 2025, the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) amended and restated the Company’s bylaws (the “Amended and Restated Bylaws”) to change the voting standard for the election of directors from a plurality to a majority voting standard, except in a contested election, where a plurality vote shall apply.”
Alexander Johnson departed as President of Patient and Testing Services at CareDx, Inc..
“On September 12, 2024, CareDx, Inc. (the “Company”) announced that the Company reached an agreement with Alexander Johnson, the Company’s President of Patient and Testing Services, pursuant to which Mr. Johnson’s employment would conclude effective as of September 13, 2024 and that such separation would be treated as a termination by the Company without “cause””
Keith Kennedy was appointed as Chief Operating Officer at CareDx, Inc..
“The Board of Directors of CareDx, Inc. (the “Company”) has appointed Keith Kennedy, as the Company’s Chief Operating Officer, effective September 12, 2024 (the “Effective Date”).”
CareDx, Inc. reported the first quarter ended March 31, 2024 results: revenue $72.0 million, net income net loss was $16.7 million, EPS $0.32. Guidance raised.
“CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights • Reported first quarter revenue of $72.0 million. • Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. • Grew testing services patients results for the third consecutive”
John W. Hanna was appointed as Class III director at CareDx, Inc..
“The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).”
John W. Hanna was appointed as President and Chief Executive Officer at CareDx, Inc..
“The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).”
R. Bryan Riggsbee was appointed as Director at CareDx, Inc..
“On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.”
CareDx, Inc. reported the full year ended December 31, 2023 results: revenue between $279 million and $280 million.
“Preliminary revenue for the full year ended December 31, 2023, is expected to be between $279 million and $280 million”
CareDx, Inc. reported the fourth quarter ended December 31, 2023 results: revenue between $65 million and $66 million.
“Preliminary revenue for the three months ended December 31, 2023, is expected to be between $65 million and $66 million”
CareDx, Inc. reported the third quarter ended September 30, 2023 results: revenue $67.2 million, net income $23.5 million, EPS $0.43. Guidance raised.
“for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights • Reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and”
Reginald Seeto changed role as Senior Advisor to the Chairperson at CareDx, Inc..
“effective November 2, 2023, he will transition to the role of Senior Advisor to the Chairperson”
Reginald Seeto resigned as Director at CareDx, Inc..
“Dr. Seeto also resigned from the Board, effective as of November 1, 2023.”
Reginald Seeto resigned as President and Chief Executive Officer at CareDx, Inc..
“Reginald Seeto, MBBS, the President and Chief Executive Officer of CareDx, Inc. (the “Company”), resigned from the Company.”
Abraham Ronai changed role as Senior Legal Advisor to the Chairperson at CareDx, Inc..
“effective October 1, 2023, he will transition to the role of Senior Legal Advisor to the Chairperson of the Board of Directors of the Company”
Abraham Ronai resigned as Chief Administrative & Legal Officer and Secretary at CareDx, Inc..
“On September 20, 2023, Abraham Ronai, the Chief Administrative & Legal Officer and Secretary of CareDx, Inc. (the “Company”), resigned from the Company.”
CareDx, Inc.: Amendment to Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation (effective 2023-06-16).
“At the Annual Meeting, the stockholders of the Company approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to provide for the gradual declassification of the board of directors (the “Board of Directors”) of the Company (the “Declassification Amendment”) and (ii) an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation (the “Officer Exculpation Amendment”).”
CareDx, Inc.: Amendment to Certificate of Incorporation to provide for gradual declassification of the Board of Directors (effective 2023-06-16).
“On June 15, 2023, CareDx, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to provide for the gradual declassification of the board of directors (the “Board of Directors”) of the Company (the “Declassification Amendment”)”
CareDx, Inc. reported the first quarter ended March 31, 2023 results: revenue $77.3 million, net income net loss of $23.7 million, EPS basic and diluted net loss per share of $0.44.
“test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%. • Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with approximately 3,200 AlloSure Kidney Medicare tests that the Company did not”
CareDx, Inc. amended Agreement Regarding Payment of Royalties and Amendment to the Amended and Restated Exclusive License Agreement with Stanford University (effective 2023-02-03).
“On March 29, 2023, the Parties entered into an Agreement Regarding Payment of Royalties and Amendment to the Amended and Restated Exclusive License Agreement (the “Agreement and Amendment”).”
CareDx, Inc.: Amended and restated bylaws to address universal proxy rules and enhance disclosure requirements for director nominations and stockholder proposals (effective 2023-03-24).
“On March 24, 2023, the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date.”
CareDx, Inc. reported full year ended December 31, 2022 results: revenue $321.8 million, net income $76.6 million, EPS $1.44.
“Revenue for the full year ended December 31, 2022, was $321.8 million, an increase of 9% compared with $296.4 million in 2021. Testing services revenue for the full year ended December 31, 2022 was $263.7 million, compared with $259.3 million in 2021. Product revenue for the full year ended December 31, 2022 was $29.3 million, compared to $26.8 million in 2021. Patient and digital solutions revenue for the full year 2022 was $28.8 million, compared to $10.3 million in 2021. Net loss for the full year ended December 31, 2022 was $76.6 million, compared to a net loss of $30.7 million in 2021. Basic and diluted net loss per share for the full year ended December 31, 2022 was $1.44, compared to basic and diluted net loss per share of $0.59 in the full year ended December 31, 2021.”
CareDx, Inc. reported three months ended December 31, 2022 results: revenue $82.4 million, net income $18.3 million, EPS $0.34.
“Revenue for the three months ended December 31, 2022 was $82.4 million, an increase of 4% compared with $79.2 million in the fourth quarter of 2021. Testing services revenue for the quarter was $65.4 million, compared with $68.7 million in the same period in 2021. Total AlloSure ® and AlloMap ® patient results provided in the quarter were 47,700, including 2,300 AlloSure ® Lung patient results. Product revenue in the three months ended December 31, 2022 was $8.6 million, compared to $7.7 million in the same period in 2021. Patient and digital solutions revenue in the fourth quarter of 2022 was $8.4 million, compared to $2.9 million in the same period in 2021. For the fourth quarter of 2022, net loss was $18.3 million, compared to a net loss of $16.2 million in the same period in 2021. Basic and diluted net loss per share in the fourth quarter of 2022 was $0.34, compared to basic and diluted net loss per share of $0.31 in the fourth quarter of 2021.”
CareDx, Inc. reported the full year ended December 31, 2022 results: revenue $321.3 million to $321.6 million.
“Preliminary revenue for the full year ended December 31, 2022, is expected to be between $321.3 million and $321.6 million”
CareDx, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $81.9 million to $82.2 million.
“Preliminary revenue for the three months ended December 31, 2022, is expected to be between $81.9 million and $82.2 million”
Ralph Snyderman departed as Director at CareDx, Inc..
“On November 21, 2022, Ralph Snyderman, M.D., notified the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) that he will be resigning from the Board and all committees of the Board, effective as of December 31, 2022.”
CareDx, Inc. reported the third quarter ended September 30, 2022 results: revenue $79.4 million, net income net loss was $16.9 million, EPS $0.32.
“with positive adjusted EBITDA by first half of 2023 • Delivered 46,500 patient test results, representing growth of 15% compared to third quarter of 2021 • Achieved revenue of $79.4 million, increasing 5% year-over-year • Sustained strong testing services GAAP gross margin of 73% and non-GAAP gross margin of 74% • Strong balance sheet with $291 million cash, cash”
Abraham Ronai was appointed as Chief Administrative & Legal Officer and Secretary at CareDx, Inc..
“Effective September 7, 2022, the Company appointed Abraham Ronai, age 49, as the Company’s Chief Administrative & Legal Officer and Secretary.”
Abhishek Jain was appointed as Chief Financial Officer at CareDx, Inc..
“Effective September 7, 2022, CareDx, Inc. (the “Company”) appointed Abhishek Jain, age 46, as the Company’s Chief Financial Officer.”
Sasha King resigned as Chief Marketing Officer at CareDx, Inc..
“On August 30, 2022, Sasha King, the Chief Marketing Officer of CareDx, Inc. (the “Company”), notified the Company of her intent to resign from the Company, effective as of the end of the day on September 16, 2022, to pursue another career opportunity.”
Abhishek Jain was appointed as Interim Chief Financial Officer at CareDx, Inc..
“The Company appointed Abhishek Jain, age 46, as the Company’s Interim Chief Financial Officer, effective May 26, 2022.”
Ankur Dhingra resigned as Chief Financial Officer at CareDx, Inc..
“On May 18, 2022, Ankur Dhingra, the Chief Financial Officer (principal accounting and financial officer) of CareDx, Inc. (the “Company”), notified the Company of his intent to resign from the Company, effective as of the end of the day on May 25, 2022, to pursue another career opportunity.”
Michael D. Goldberg was appointed as Chair of the Board at CareDx, Inc..
“Effective November 1, 2021, Michael D. Goldberg, the Company’s lead independent director, was appointed as the Chair of the Board, a position he previously held from 2011 to 2019.”
Peter Maag changed role as Non-Employee Member of the Board at CareDx, Inc..
“On November 1, 2021, Peter Maag, Ph.D., the Executive Chair of the Board of Directors of CareDx, Inc. (the “Company”), transitioned from his position as Executive Chair of the Board of Directors of the Company (the “Board”) to a non-employee member of the Board.”
Arthur A. Torres was appointed as Director at CareDx, Inc..
“On September 11, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Arthur A. Torres as a Class III director of the Company.”
Alex Johnson was appointed as Chief Business Officer and Head of Testing Services at CareDx, Inc..
“Effective July 19, 2021, CareDx, Inc. (the “Company”) appointed Alex Johnson, age 47, as the Company’s Chief Business Officer and Head of Testing Services.”
Hannah A. Valantine was appointed as Class I Director at CareDx, Inc..
“On June 30, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Hannah A. Valantine, M.D. as a Class I director of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.